Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.
Kopmar NE, Othus M, Quach K, Rasmussen A, Schonhoff K, Becker PS, Walter RB, Halpern AB, Salit R, Cassaday RD, Shustov A, Stewart FM, Oehler VG, Scott BL, Sandmaier BM, Lee SJ, Estey EH, Percival MM. Kopmar NE, et al. Among authors: percival mm. Transplant Cell Ther. 2024 May 5:S2666-6367(24)00376-2. doi: 10.1016/j.jtct.2024.05.002. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38710302
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.
Hochman MJ, Othus M, Hasserjian RP, Ambinder A, Brunner A, Percival MM, Hourigan CS, Swords R, DeZern AE, Estey EH, Karp JE. Hochman MJ, et al. Among authors: percival mm. Leukemia. 2023 Sep;37(9):1915-1918. doi: 10.1038/s41375-023-01985-y. Epub 2023 Jul 31. Leukemia. 2023. PMID: 37524919 Free PMC article.
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Halpern AB, Rodríguez-Arbolí E, Othus M, Garcia KA, Percival MM, Cassaday RD, Oehler VG, Becker PS, Appelbaum JS, Abkowitz JL, Orozco JJ, Keel SB, Hendrie PC, Scott BL, Ghiuzeli MC, Estey EH, Walter RB. Halpern AB, et al. Among authors: percival mm. Blood Adv. 2023 Sep 12;7(17):4950-4961. doi: 10.1182/bloodadvances.2023010392. Blood Adv. 2023. PMID: 37339483 Free PMC article. Clinical Trial.
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
Cassaday RD, Zarling LC, Garcia KA, Sala-Torra O, Stevenson PA, Martino CH, Liu YJ, Fang M, Percival MM, Halpern AB, Becker PS, Oehler VG, Shustov AR, Cooper JP, Orozco JJ, Hendrie PC, Walter RB, Radich JP, Soma LA, Estey EH. Cassaday RD, et al. Among authors: percival mm. Leuk Lymphoma. 2023 May;64(5):927-937. doi: 10.1080/10428194.2023.2189803. Epub 2023 Mar 20. Leuk Lymphoma. 2023. PMID: 36938892 Free PMC article. Clinical Trial.
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
Kopmar NE, Gooley T, Curley N, Russell K, Shaw C, Schonhoff K, Lim J, Halpern AB, Walter RB, Scott BL, Appelbaum J, Hendrie PC, Estey EH, Percival MM. Kopmar NE, et al. Among authors: percival mm. Leuk Lymphoma. 2023 May;64(5):1057-1059. doi: 10.1080/10428194.2023.2185087. Epub 2023 Mar 9. Leuk Lymphoma. 2023. PMID: 36896478 Free PMC article. Clinical Trial. No abstract available.
39 results